US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
biotech · TCR-T Cells · B-ALL · TCRX
TScan Therapeutics
TScan Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waltham, USA HQ
2018 Founded
152 Employees
Public company Type
TCRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 9
- Drugs
- 5
- Patents
- 0
TScan Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
TScan Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to TScan Therapeutics in public FDA and regional records.
-
Development asset linked to TScan Therapeutics in public FDA and regional records.
-
Development asset linked to TScan Therapeutics in public FDA and regional records.